latest update:
[TrialBase DB]

trial summary · NCT07430202

A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

A Phase 1b Study of a DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab for Patients With Advanced Stage Fibrolamellar Hepatocellular Carcinoma (FLC)

Trial record from the TrialBase DB dataset, status RECRUITING, condition Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)), sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07430202phase PHASE1enrollment 27start 2026-10-28

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

The purpose of this study is to determine whether the combination of a neoantigen vaccine targeting the DNAJB1-PRKACA fusion kinase in combination with DRP-104, Nivolumab and Ipilimumab is safe and yields a clinically compelling antitumor activity measured as based on objective response rate (ORR, assessed by RECIST 1.1). Secondary objectives include progression-free survival (PFS) and overall survival (OS).

Source record: https://clinicaltrials.gov/study/NCT07430202

Facts

registry idNCT07430202
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE1
study typeINTERVENTIONAL
lead conditionLiver Cancer (Fibrolamellar Hepatocellular Cancer (FLC))
sponsorSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
sponsor classOTHER
enrollment27
start date2026-10-28
primary completion2030-10
completion2030-10
results postednot reported

Conditions

  • Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC))

Interventions

  • DNAJB1-PRKACA Peptide Vaccine
  • DRP-104
  • Nivolumab
  • Ipilimumab

Countries

  • United States

Intervention types: DRUG

Work with this record